NeuroThera Labs Secures Batch Release for SCI-110 Phase IIb Tourette Trial

• NeuroThera Labs completed SCI-110 manufacturing and secured European batch release certification, clearing shipments for its FDA-authorized Phase IIb Tourette syndrome trial.
• All three sites in the United States, Germany and Israel completed initiation activities, positioning the trial to begin patient enrollment.
• The study will evaluate the cannabinoid-based oral treatment’s efficacy, safety and tolerability in adults; the announcement covers operational progress, not clinical results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurothera Labs Inc. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202610220812TNWSWRCACNPR_____1BKRFazqD) on October 22, 2026, and is solely responsible for the information contained therein.